IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society: December 5-9, 2010, San Diego, CA USA

mAbs

Volumn 3, Issue 2, 2011, Pages 133-152

  Arnett, Samantha O ^a   Teillaud, Jean Luc ^b   Wurch, Thierry ^c   Reichert, Janice M ^d   Dunlop, Cameron ^a,e   Huber, Michael ^a,e  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^d mAbs   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; NANOPARTICLE; NATALIZUMAB; NEUTRALIZING ANTIBODY; PRO 140; RITUXIMAB; ANTIBODY; BIOLOGICAL PRODUCT; PEPTIDE LIBRARY;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; DRUG TOLERABILITY; EFFECTOR CELL; GENE DELETION; GENE SILENCING; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOTHERAPY; INJECTION SITE REACTION; INTRACELLULAR TRANSPORT; KIDNEY CARCINOMA; LYMPHOMA CELL; NONHUMAN; PATENT; PHAGE DISPLAY; RADIOIMMUNOTHERAPY; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; INTERNATIONAL COOPERATION; MEDICAL SOCIETY; METHODOLOGY; MOUSE; PHARMACOKINETICS; PROTEIN ENGINEERING; UNITED STATES;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOTHERAPY; INTERNATIONALITY; MICE; PEPTIDE LIBRARY; PROTEIN ENGINEERING; SOCIETIES, MEDICAL; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 79952729049     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.2.14939     Document Type: Conference Paper

References (14)

1. d'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009; 33:465-73.
2. Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011; 3:38-48.
3. Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, et al. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum 2010; 62:1933-43.
4. Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 2010; 399:436-49.
5. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147-57. (Pubitemid 41486396)
6. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429-40.
7. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76-99.
8. Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010; 10:489-91.
9. Burris HA, 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate Trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29:398-405.
10. Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. mAbs 2009; 1:128-41.
11. Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med 2010; 40:167-81.
12. Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, et al. ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel 2010; 23:243-9.
13. Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-402.
14. Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, et al. Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. Mol Cancer Ther 2011; 10:178-85.